JP5744412B2 - Furosemide formulation - Google Patents
Furosemide formulation Download PDFInfo
- Publication number
- JP5744412B2 JP5744412B2 JP2010072339A JP2010072339A JP5744412B2 JP 5744412 B2 JP5744412 B2 JP 5744412B2 JP 2010072339 A JP2010072339 A JP 2010072339A JP 2010072339 A JP2010072339 A JP 2010072339A JP 5744412 B2 JP5744412 B2 JP 5744412B2
- Authority
- JP
- Japan
- Prior art keywords
- furosemide
- tablet
- coating
- film
- coating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 title claims description 33
- 229960003883 furosemide Drugs 0.000 title claims description 32
- 239000000203 mixture Substances 0.000 title description 8
- 238000009472 formulation Methods 0.000 title description 5
- 238000002360 preparation method Methods 0.000 claims description 29
- 239000003826 tablet Substances 0.000 claims description 27
- 239000011248 coating agent Substances 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 18
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 11
- 229920003169 water-soluble polymer Polymers 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims 1
- 239000004503 fine granule Substances 0.000 claims 1
- 229920000578 graft copolymer Polymers 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 238000000576 coating method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 238000004040 coloring Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 5
- 239000007941 film coated tablet Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 229960003511 macrogol Drugs 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- -1 sucrose fatty acid ester Chemical class 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229940106705 chlorophyll Drugs 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000006103 coloring component Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明はフロセミド製剤に関し、更に詳細には、経時的に生じる着色を抑制した固形のフロセミド製剤に関する。 The present invention relates to a furosemide preparation, and more particularly to a solid furosemide preparation that suppresses coloration that occurs over time.
フロセミド(Furosemide;化学名 5−(アミノスルホニル)−4−クロロ−2−[(2−フラニルメチル)アミノ]安息香酸)は、ループ利尿薬のひとつであり、ヘンレのループの太い上行脚の管腔側の膜のNa+・K+・2Cl−共輸送担体を抑制することにより、NaCl、K+の再吸収を抑制し、速効性かつ強力な利尿作用を示す薬剤である。 Furosemide (chemical name 5- (aminosulfonyl) -4-chloro-2-[(2-furanylmethyl) amino] benzoic acid) is one of the loop diuretics and the lumen of the thick ascending limb of Henle's loop By suppressing the Na + · K + · 2Cl − cotransport carrier in the side membrane, it is a drug that suppresses reabsorption of NaCl and K + and exhibits a fast-acting and powerful diuretic action.
このフロセミドは光に対して着色することが知られており、フロセミドを含む製剤はすでに市販されているが、その素錠状態では経時的に着色が発生している。しかし、昨今、自動分封機のような光を遮断する容器にフロセミドを含有した錠剤を保管した場合にも、光に対して着色したと同じように着色することが確認されている(非特許文献1)。 This furosemide is known to be colored with respect to light, and preparations containing furosemide are already on the market, but in the uncoated tablet state, coloring occurs over time. However, recently, even when a tablet containing furosemide is stored in a light blocking container such as an automatic separator, it is confirmed that it is colored in the same manner as when colored against light (non-patent document). 1).
このようなフロセミド製剤の着色は商品的には着色は望ましくない現象であり、この着色の原因を見出し、着色を防止する手段の開発が求められていた。 The coloring of such furosemide preparations is a phenomenon in which coloring is not desirable for commercial purposes, and the cause of this coloring has been found and development of means for preventing the coloring has been required.
本発明は上記実情に鑑みなされたものであり、フロセミドを含有しながら、着色が防止された固形製剤の提供をその課題とするものである。 The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a solid preparation containing furosemide and prevented from being colored.
本発明者らは、上記課題を解決すべく、まずフロセミド含有固形製剤での着色の原因と目される要因について広く検討した結果、この着色成分は、微量のフロセミドの加水分解物であることが明らかになった。そして更に、この着色を防止する手段に関し研究を行った結果、フロセミドを含有する固形製剤を、水溶性高分子と酸化された金属を含む皮膜で被覆することにより、上記着色は防止しうることを見出し、本発明を完成した。 In order to solve the above-mentioned problems, the present inventors have extensively studied the factors considered to be the cause of coloring in the furosemide-containing solid preparation, and as a result, the coloring component is a very small amount of furosemide hydrolyzate. It was revealed. Furthermore, as a result of research on the means for preventing this coloration, it was confirmed that the above coloration can be prevented by coating a solid preparation containing furosemide with a film containing a water-soluble polymer and an oxidized metal. The headline and the present invention were completed.
すなわち本発明は、フロセミドを含有する固形製剤の表面を、水溶性高分子と酸化された金属を含有するコーティング剤で被覆してなるフロセミド製剤である。 That is, the present invention is a furosemide preparation obtained by coating the surface of a solid preparation containing furosemide with a coating agent containing a water-soluble polymer and an oxidized metal.
本発明のフロセミド製剤は、経時的に着色することがないので、特殊な容器を必要とせず、更に、複数の薬剤を一つの袋に包装するワンドースパッケージが可能となり、商品性の高い医薬品とすることができる。 Since the furosemide preparation of the present invention does not color over time, a special container is not required, and a one-dose package in which a plurality of drugs are packaged in a single bag is possible. can do.
本発明のフロセミド製剤は、フロセミドを含有する固形製剤の表面を、水溶性高分子と酸化された金属を含有するコーティング剤で被覆することにより調製される。 The furosemide preparation of the present invention is prepared by coating the surface of a solid preparation containing furosemide with a coating agent containing a water-soluble polymer and an oxidized metal.
フロセミドを含有する固形製剤としては、錠剤、顆粒剤、細粒剤、散剤等が挙げられるが、錠剤が好ましい。またこの固形製剤中に含有されるフロセミド量は特に制限はないが、好ましくは1ないし50質量%(以下、単に「%」で示す)、更に好ましくは2.5ないし30%が好ましい。 Examples of the solid preparation containing furosemide include tablets, granules, fine granules, and powders, with tablets being preferred. The amount of furosemide contained in the solid preparation is not particularly limited, but is preferably 1 to 50% by mass (hereinafter simply referred to as “%”), more preferably 2.5 to 30%.
この固形製剤は、フロセミドを含有する以外は、常法により製造することができる。すなわち、公知の賦形剤とフロセミドを混合して固形製剤用組成物とし、これを常法に従って製剤化すればよい。使用される賦形剤の例としては、例えば、乳糖、マンニトール、キシリトール、ソルビトール、エリスリトール等の糖アルコール、精製白糖、結晶セルロース、粉末セルロース、デキストラン、デキストリン、ブドウ糖、粉糖、トウモロコシデンプン、バレイショデンプン、コメデンプン等が挙げられる。 This solid preparation can be produced by a conventional method except that it contains furosemide. That is, a known excipient and furosemide may be mixed to form a solid formulation composition, which may be formulated according to a conventional method. Examples of excipients used include, for example, sugar alcohols such as lactose, mannitol, xylitol, sorbitol, erythritol, purified white sugar, crystalline cellulose, powdered cellulose, dextran, dextrin, glucose, powdered sugar, corn starch, potato starch And rice starch.
また、必要によって、適宜、従来公知の任意成分、例えば、種々の滑沢剤、可溶化剤、緩衝剤、吸着剤、結合剤、懸濁化剤、抗酸化剤、充填剤、pH調整剤、分散剤、崩壊剤、崩壊補助剤、防湿剤、防腐剤、溶剤、溶解補助剤、流動化剤等を加えることができる。このうち崩壊剤としては、例えば、カルメロース、カルメロースカルシウム、クロスカルメロースナトリウム、低置換度ヒドロキシプロピルメチルセルロース、結晶セルロース、ヒドロキシプロピルスターチ、部分アルファー化デンプン、クロスポビドン等を挙げることができる。結合剤としては、例えば、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、メチルセルロース、カルメロースナトリウム、ポリビニルアルコール、ポリビニルピロリドン等を挙げることができる。流動化剤として、例えば、含水二酸化ケイ素、軽質無水ケイ酸、合成ケイ酸アルミ、タルク、メタケイ酸アルミン酸マグネシウム等が挙げられる。滑択剤としては、例えば、ステアリン酸、ステアリン酸カルシウム、ステアリン酸マグネシウム、硬化油、ショ糖脂肪酸エステル、フマル酸ステアリルアルコール、タルク、マクロゴール等を挙げることができる。 If necessary, conventionally known optional components such as various lubricants, solubilizers, buffers, adsorbents, binders, suspending agents, antioxidants, fillers, pH adjusters, A dispersing agent, a disintegrating agent, a disintegrating aid, a moisture proofing agent, a preservative, a solvent, a solubilizing aid, a fluidizing agent, and the like can be added. Among these, examples of the disintegrant include carmellose, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropyl methylcellulose, crystalline cellulose, hydroxypropyl starch, partially pregelatinized starch, and crospovidone. Examples of the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, carmellose sodium, polyvinyl alcohol, polyvinylpyrrolidone and the like. Examples of the fluidizing agent include hydrous silicon dioxide, light anhydrous silicic acid, synthetic aluminum silicate, talc, magnesium aluminate metasilicate, and the like. Examples of the lubricant include stearic acid, calcium stearate, magnesium stearate, hydrogenated oil, sucrose fatty acid ester, stearyl alcohol fumarate, talc, macrogol and the like.
上記固形製剤用組成物を用い、錠剤(素錠)を調製するには、必要によりこの組成物を顆粒化した後、常法により圧縮成型をすればよい。 In order to prepare a tablet (plain tablet) using the composition for a solid preparation, the composition may be granulated if necessary and then compression molded by a conventional method.
顆粒化する方法としては、通常用いられる方法で実施すればよい。具体的には、流動層造粒、攪拌造粒、押出造粒、ワースター式造粒若しくはこれらを組み合わせた方法が挙げられる。なお、これ以外の方法でも、次工程の圧縮成型に支障を来たさないようであれば、別の方法でも特段問題ない。 What is necessary is just to implement by the method used normally as a method of granulating. Specific examples include fluidized bed granulation, stirring granulation, extrusion granulation, Wurster granulation, or a combination thereof. Note that other methods are not particularly problematic as long as they do not hinder the compression molding of the next step.
圧縮成型の方法としては、錠剤を形成できればどのような方法でも特段問題はない。具体的には、例えば、ロータリー打錠機、単発打錠機などが挙げられるが、これらに限定するものではない。 Any compression molding method can be used as long as it can form tablets. Specific examples include a rotary tableting machine and a single-shot tableting machine, but are not limited thereto.
以上のようにして調製される固形製剤は、次に水溶性高分子と酸化された金属を含有するコーティング剤で被覆される。 The solid preparation thus prepared is then coated with a coating agent containing a water-soluble polymer and an oxidized metal.
コーティング剤に配合される水溶性高分子としては、例えば、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、ポリビニルアルコール、メチルセルロース、ポリビニルピロリドン等が挙げられ、このうちヒドロキシプロピルメチルセルロースが好ましい。また、酸化された金属としては、例えば、酸化チタン、黄色三二酸化鉄、三二酸化鉄等が挙げられ、このうち酸化チタンが好ましい。 Examples of the water-soluble polymer blended in the coating agent include hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinyl alcohol, methylcellulose, polyvinylpyrrolidone and the like, among which hydroxypropylmethylcellulose is preferable. Examples of the oxidized metal include titanium oxide, yellow iron sesquioxide, and iron sesquioxide. Among these, titanium oxide is preferable.
上記コーティング剤は、前記水溶性高分子と酸化された金属を、精製水、エチルアルコール、プロパノール、塩化メチレン、メタノール等若しくはこれらの混合溶液の溶媒に溶解ないし懸濁することにより調製されるが、この溶媒をのぞいた皮膜形成成分中の水溶性高分子の量は、50ないし90%程度であり好ましくは60ないし70%である。酸化された金属の量は、1ないし40%程度であり、好ましくは5ないし30%である。 The coating agent is prepared by dissolving or suspending the water-soluble polymer and the oxidized metal in a solvent of purified water, ethyl alcohol, propanol, methylene chloride, methanol, or a mixed solution thereof. The amount of the water-soluble polymer in the film-forming component excluding this solvent is about 50 to 90%, preferably 60 to 70%. The amount of oxidized metal is about 1 to 40%, preferably 5 to 30%.
また、本発明の効果を損なわない範囲で、他の添加剤等についてもコーティング剤中に添加することが出来る。具体的には、可塑剤、光沢剤、着色剤等を添加することも出来る。可塑剤としては、例えばマクロゴール、クエン酸トリエチル、グリセリン、グリセリン脂肪酸エステル、トリアセチン、ひまし油、ポリソルベート、プロピレングリコール等を含有することが出来る。また、着色剤として、先に記載した酸化された金属以外にも、例えば、黄色5号、黄色4号アルミニウムレーキ、青色1号、赤色2号等のレーキ色素、銅クロロフィル、フェノールレッド、メチレンブルー、ベータカロチン、カラメル等を含有することが出来る。また、光沢剤としては、例えば、セタノール、硬化油、サラシミツロウ、ステアリン酸、ステアリン酸カルシウム、ステアリン酸マグネシウム、マクロゴール等を含有することができる。 In addition, other additives can be added to the coating agent as long as the effects of the present invention are not impaired. Specifically, a plasticizer, a brightener, a colorant, and the like can be added. Examples of the plasticizer may include macrogol, triethyl citrate, glycerin, glycerin fatty acid ester, triacetin, castor oil, polysorbate, propylene glycol, and the like. In addition to the oxidized metal described above as a colorant, for example, yellow No. 5, yellow No. 4 aluminum lake, blue No. 1, red No. 2 and other lake pigments, copper chlorophyll, phenol red, methylene blue, Beta carotene, caramel and the like can be contained. Further, as the brightener, for example, cetanol, hydrogenated oil, white beeswax, stearic acid, calcium stearate, magnesium stearate, macrogol and the like can be contained.
これらのコーティング液はコーティングを実施する直前に調整することが可能であるが、市販されている調整済みのコーティング液を使用することも出来る。具体的には、オパドライ(日本カラコン)等が挙げられる。 These coating liquids can be adjusted immediately before the coating is performed, but commercially available adjusted coating liquids can also be used. Specific examples include Opadry (Nippon Colorcon).
前記固形製剤をコーティング剤で被覆する方法も公知の方法で良く、例えば、流動層造粒、ドリップ型コーティング、パンコーティング
等の方法を適宜利用することができる。この被覆に当たっての、固形製剤とコーティング剤の使用割合は、固形製剤の具体的形態によっても相違するが、錠剤の場合、固形製剤100部に対し、コーティング剤を1ないし20部程度、好ましくは3ないし10部程度とすればよい。
The method for coating the solid preparation with a coating agent may be a known method, and for example, methods such as fluidized bed granulation, drip-type coating, pan coating and the like can be appropriately used. The ratio of the solid preparation and the coating agent used in the coating varies depending on the specific form of the solid preparation. In the case of a tablet, about 1 to 20 parts, preferably 3 parts of the coating agent is used per 100 parts of the solid preparation. Or it may be about 10 parts.
また、水溶性高分子と酸化された金属を含有したフィルムコーティングを行った後、発明の効果を損なわない範囲で、持続性を付与させたり、胃溶性、腸溶性を保持させたりすることが出来る。また、コーティングの後、糖を用いた糖衣錠にすることも可能である。 In addition, after coating a film containing a water-soluble polymer and an oxidized metal, it is possible to impart sustainability or maintain gastric and enteric properties within a range that does not impair the effects of the invention. . It is also possible to form sugar-coated tablets using sugar after coating.
次に実施例を挙げ、本発明を更に詳しく説明するが、本発明はこれら実施例に何ら制約されるものではない。 EXAMPLES Next, although an Example is given and this invention is demonstrated in more detail, this invention is not restrict | limited at all by these Examples.
実 施 例 1
フロセミド製剤(錠剤)の調製:
下記の製剤処方により、医薬組成物を調製し、これを流動層造粒機にて造粒を実施して、得られた顆粒を用い、打錠を使用して直径6.1mm、厚さ2.9mmおよび重さ90mgの素錠を調製した。得られた素錠に対し、下記組成のコーティング剤を、精製水に懸濁し、乾燥後の皮膜が1錠あたり7mgとなるようドリアコーター中で噴霧し、フィルムコーティング剤を調製した。
Example 1
Preparation of furosemide formulation (tablets):
A pharmaceutical composition was prepared according to the following formulation, and granulated with a fluidized bed granulator. The resulting granule was used and a tablet was used to make a diameter of 6.1 mm and a thickness of 2 An uncoated tablet with a diameter of 9 mm and a weight of 90 mg was prepared. A coating agent having the following composition was suspended in purified water on the obtained uncoated tablets and sprayed in a doria coater so that the dried film was 7 mg per tablet to prepare a film coating agent.
< 製剤処方 >
成 分 名 配合量(mg)
フロセミド 20.0
乳糖水和物 19.0
トウモロコシデンプン 19.5
結晶セルロース 18
軽質無水ケイ酸 0.9
部分アルファー化デンプン 9
アルファー化デンプン 1.8
軽質無水ケイ酸 0.9
ステアリン酸マグネシウム 0.9
計 90.0
<Prescription formulation>
Component name Compounding amount (mg)
Furosemide 20.0
Lactose hydrate 19.0
Corn starch 19.5
Crystalline cellulose 18
Light anhydrous silicic acid 0.9
Partially pregelatinized starch 9
Alphalated starch 1.8
Light anhydrous silicic acid 0.9
Magnesium stearate 0.9
Total 90.0
< コーティング剤処方 >
成 分 名 配合量(mg)
ヒドロキシプロピルメチル 4.5
セルロース*1
マクロゴール6000 0.7
酸化チタン 1.8
カルナウバロウ 微 量
計 7
*1 粘度:6.0mPa/s
<Coating agent formulation>
Component name Compounding amount (mg)
Hydroxypropylmethyl 4.5
Cellulose * 1
Macrogol 6000 0.7
Titanium oxide 1.8
Carnauba low amount
Total 7
* 1 Viscosity: 6.0 mPa / s
試 験 例 1
着色防止性試験(1):
実施例1により作成した素錠(直径6.1mm、厚さ2.9mm)およびそのフィルムコーティング錠並びにオイルプレスにより上記と同様の大きさの錠剤状に成型した原薬(フロセミド)について、次のようにして着色の有無を評価した。
Test example 1
Anti-coloring test (1):
For the uncoated tablet (diameter 6.1 mm, thickness 2.9 mm) prepared in Example 1, its film-coated tablet, and the drug substance (furosemide) molded into a tablet of the same size as described above with an oil press, Thus, the presence or absence of coloring was evaluated.
まず、上記の素錠、フィルムコーティング錠および錠剤状原薬の各5錠を取り、シャーレ中においた。これらに対して送風装置(扇風機)で2週間空気を送風した。次いで、空気接触面における色差(ΔE)を分光色彩計(SE−2000;日本電色工業(株)製)を用いて調べた。なお、ΔEの基準値であるLabは、試験開始時の各錠剤の値を用いた。また、試験結果は、各錠剤5錠の平均値とした。この結果を表1に示す。 First, 5 tablets each of the above-mentioned uncoated tablet, film-coated tablet and tablet-form drug substance were taken and placed in a petri dish. For these, air was blown for 2 weeks with a blower (fan). Next, the color difference (ΔE) on the air contact surface was examined using a spectrocolorimeter (SE-2000; manufactured by Nippon Denshoku Industries Co., Ltd.). Note that as the reference value of ΔE, the value of each tablet at the start of the test was used. Moreover, the test result was made into the average value of 5 tablets each. The results are shown in Table 1.
< 試験条件 >
温 度 25℃ 暗室
風 5.4m/sec
試験期間 1週間若しくは2週間
<Test conditions>
Temperature 25 ℃ Dark room Wind 5.4m / sec
Test period 1 week or 2 weeks
< 結 果 >
この結果から明らかなように、フロセミドを含有した素錠よりも、これにフィルムコーティングを施した錠剤ほうが色差の変化が少ないことが判明した。 As is clear from this result, it was found that the color difference of the tablet coated with film coating was less than that of the uncoated tablet containing furosemide.
試 験 例 2
着色防止性試験(2):
着色が単にフィルムコーティングで隠されているだけであり、素錠は着色している可能性もあるので、試験例1で2週間送風を受けた後のフィルムコーティング錠について、内部の着色状況を調べた。
Test example 2
Anti-coloring test (2):
Since the coloration is simply hidden by the film coating, and the uncoated tablet may be colored, the internal coloration state of the film-coated tablet after receiving a blast for 2 weeks in Test Example 1 was examined. It was.
調査は、フィルムコーティング錠からコーティングフィルムをはぎ取り、素錠の状態とした後、分光色彩計(SE−2000)を用いてΔEの確認を行った。なお、ΔEの基準値は、製造直後のフィルムコーティング錠のコーティングフィルムをはいだときの値を用いた。試験結果については1錠の測定における繰り返し回数3の平均値を用いた。この結果、着色防止試験を受けたフィルムコーティング剤の内部の素錠のΔEは、0.68であり、ほとんど着色していないことがわかった。 In the investigation, the coating film was peeled off from the film-coated tablet to obtain an uncoated tablet, and then ΔE was confirmed using a spectrocolorimeter (SE-2000). The reference value for ΔE was the value obtained when the coated film of the film-coated tablet immediately after production was removed. About the test result, the average value of the repetition frequency 3 in the measurement of 1 tablet was used. As a result, it was found that ΔE of the uncoated tablet in the film coating agent subjected to the anti-coloring test was 0.68, which was hardly colored.
本発明のフロセミド製剤は、経時的に着色することがないので、商品性の高い医薬品として利用することができる。
Since the furosemide preparation of the present invention does not color with time, it can be used as a highly commercial drug.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010072339A JP5744412B2 (en) | 2010-03-26 | 2010-03-26 | Furosemide formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010072339A JP5744412B2 (en) | 2010-03-26 | 2010-03-26 | Furosemide formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011201830A JP2011201830A (en) | 2011-10-13 |
JP5744412B2 true JP5744412B2 (en) | 2015-07-08 |
Family
ID=44878895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010072339A Active JP5744412B2 (en) | 2010-03-26 | 2010-03-26 | Furosemide formulation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5744412B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6133073B2 (en) * | 2013-02-08 | 2017-05-24 | 株式会社三和化学研究所 | Pharmaceutical formulation containing loop diuretic as active ingredient |
US10017714B2 (en) | 2015-05-19 | 2018-07-10 | Ecolab Usa Inc. | Efficient surfactant system on plastic and all types of ware |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2745500B1 (en) * | 1996-03-04 | 1998-04-03 | Synthelabo | SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING MIZOLASTINE |
DE102004031835A1 (en) * | 2004-06-30 | 2006-01-19 | Basf Ag | Fast-dispersible, finely divided, non-segregating powdery film coating composition based on polyvinyl alcohol-polyether graft copolymers characterized by particular physical stability and low roughness |
US20090148480A1 (en) * | 2005-07-15 | 2009-06-11 | Kissei Pharmaceutical Co., Ltd. | Sustained release preparation |
WO2007052592A1 (en) * | 2005-10-31 | 2007-05-10 | Kowa Co., Ltd. | Pharmaceutical preparation having excellent photostability |
JP2008169173A (en) * | 2007-01-15 | 2008-07-24 | Kissei Pharmaceut Co Ltd | Sustained release preparation of carbohydrase inhibitor staying in stomach |
JPWO2008114859A1 (en) * | 2007-03-22 | 2010-07-08 | アステラス製薬株式会社 | Pharmaceutical composition containing pyrazole derivative |
-
2010
- 2010-03-26 JP JP2010072339A patent/JP5744412B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2011201830A (en) | 2011-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5794650B2 (en) | Solubility improving preparation for poorly soluble drugs | |
TWI744224B (en) | Solid preparation | |
KR20160101720A (en) | Pharmaceutical compositions comprising azd9291 | |
WO2017163170A1 (en) | Pharmaceutical composition comprising apixaban | |
JP6183979B2 (en) | Method for producing solid preparation containing aripiprazole anhydride | |
CN113423390B (en) | Afabixing preparation and preparation method thereof | |
EP3437645B1 (en) | Film-coated tablet having high chemical stability of active ingredient | |
WO2019142207A1 (en) | Pharmaceutical compositions comprising ibrutinib | |
JP5744412B2 (en) | Furosemide formulation | |
AU2017339246A1 (en) | Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof | |
JP2015193635A (en) | Fast-dissolving moisture-proof film coating preparation and production method thereof | |
JP2019034914A (en) | Levodopa-containing compact tablet having excellent sustained-release properties | |
WO2017093890A1 (en) | Clobazam tablet formulation and process for its preparation | |
JP5774308B2 (en) | Stable pharmaceutical composition of water-soluble vinorelbine salt | |
JP2021024820A (en) | Dasatinib anhydride film coating tablet having improved light stability | |
JP2020090484A (en) | Medicine tablet comprising erlotinib as active principle | |
JP6673798B2 (en) | Film-coated pharmaceutical preparation containing capecitabine as active ingredient | |
JP5065519B1 (en) | Method for producing crystalline atorvastatin calcium-containing tablet | |
JP6982290B2 (en) | Solid pharmaceutical formulation for internal use containing Onji extract | |
JP6958856B2 (en) | tablet | |
WO2023085300A1 (en) | Pharmaceutical composition having excellent elution property | |
JP2022050975A (en) | Pharmaceutical tablets comprising sunitinib malate as active ingredient | |
TR2023018145A2 (en) | MANUFACTURING METHOD FOR MYCOPHENOLATE MOFETYL FILM-COATED TABLET FORMULATIONS WITH IMPROVED DISSOLVATION RATE | |
JP2022086833A (en) | Zinc acetate-containing pharmaceutical composition | |
EP3846787A1 (en) | Novel composition of lapatinib of oral solid dosage form and method of manufacturing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140304 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150407 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150430 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5744412 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |